Proposed Data Collection Submitted for Public Comment and Recommendations, 13656-13657 [2020-04721]
Download as PDF
13656
Federal Register / Vol. 85, No. 46 / Monday, March 9, 2020 / Notices
6,125 hours. There are no other costs to
respondents other than their time.
ESTIMATED ANNUALIZED BURDEN HOURS
Total burden
(in hours)
Form
Persons Screened ............................
Informed Consent .............................
Eligible Participants ...........................
Eligibility Screening Form ................
Informed Consent Form ...................
IDU Survey .......................................
10,499
9000
9000
1
1
1
5/60
5/60
30/60
875
750
4,500
Total ...........................................
...........................................................
........................
........................
........................
6,125
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2020–04722 Filed 3–6–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–20–20HR; Docket No. CDC–2020–
0019]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
AGENCY:
ACTION:
Notice with comment period.
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on a
proposed information collection project
titled Community-Based Organizations’
Changes in Preparedness and Resources
for Support of Biomedical HIV
Prevention. The information collection
project will be used to assess
community-based organizations’ (CBOs)
awareness of, intentions to provide, and
provision of Treatment as Prevention
(TasP), non-occupational post-exposure
prophylaxis (nPEP), or pre-exposure
prophylaxis (PrEP) among clinical and
non-clinical CBOs that have received
funding from CDC’s Division of HIV/
AIDS Prevention (DHAP) and those that
applied but did not receive funding.
SUMMARY:
jbell on DSKJLSW7X2PROD with NOTICES
Average
burden per
response
(hours)
Number of
responses per
respondent
Number of
respondents
Respondent
VerDate Sep<11>2014
17:47 Mar 06, 2020
Jkt 250001
CDC must receive written
comments on or before May 8, 2020.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2020–
0019 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS–D74, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
Regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS–
D74, Atlanta, Georgia 30329; phone:
404–639–7570; Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
DATES:
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected; and
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses.
5. Assess information collection costs.
Proposed Project
Community-Based Organizations’
Changes in Preparedness and Resources
for Support of Biomedical HIV
Prevention—New—Division of HIV/
AIDS Prevention (DHAP), National
Center for HIV/AIDS, Viral Hepatitis,
STD, and TB Prevention (NCHHSTP),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
Antiretroviral (ARV) medications can
be effectively used to reduce the number
of new HIV infections. In persons
without HIV infection, ARVs can be
given as either: (1) For 28 days
following a potential HIV exposure
through sexual or injection behaviors as
nPEP or (2) begun before potential
sexual HIV exposures and taken daily
for months to years as PrEP. In persons
with HIV infection, beginning treating
with ARVs early in their infection (e.g.,
with high CD4 cell counts) can greatly
lower their risk of transmitting infection
E:\FR\FM\09MRN1.SGM
09MRN1
13657
Federal Register / Vol. 85, No. 46 / Monday, March 9, 2020 / Notices
to uninfected sexual partners; this is
also called treatment as prevention or
TasP. PrEP is 99% effective at reducing
the risk of HIV through sexual contact
when taken daily. PrEP is also 74%–
84% effective at reducing the risk of
HIV infection through injection drug use
when taken daily. Persons living with
HIV who are taking ARVs as prescribed
as well as achieving viral suppression
effectively have no risk for transmitting
the virus to an HIV-negative partner
through sexual contact. CDC is working
with various jurisdictions with high HIV
prevalence to increase capacity of ARV
provision, build collaborative efforts
between health departments and
community-based organizations, and
engage multi-sector provider systems to
reach individuals with high risk of HIV
infection as part of the End the HIV
Epidemic Initiative. CBOs will play a
crucial role in the End the HIV
Epidemic Initiative. In a previous
survey conducted by CDC’s Division of
HIV/AIDS Prevention, CBOs reported
high awareness of nPEP, PrEP, and
TasP, but their ability to meet client
need was low. Although clinical CBOs
were more prepared to support the
expansion of biomedical HIV prevention
interventions, the likelihood that all
CBOs would incorporate these
interventions if they had additional
resources was somewhat high.
Research is needed to better
understand the capacity of CBOs to
incorporate biomedical HIV prevention
be contacted from a list of CBOs that
completed the 2015 survey. In addition,
CBOs that received DHAP funding
through PS15–1502 and PS17–1704 will
also be contacted to determine their
interest in participating in the data
collection effort and to nominate a staff
member to complete the survey. Each
organization’s representative will
receive an email with a link to the
survey website (created with Survey
Monkey). The email will instruct the
representative on how to complete the
survey. Three email reminders will be
sent to organizations for those that do
not complete the survey. Where
possible, data from the 2015 survey will
be combined with data from the 2020
survey. Analyses will include
completeness (non-response rates per
item) as well as frequency of item
responses for awareness, intentions, and
provision of PrEP, nPEP, and TasP will
be assessed for all respondents
combined. Frequency and differences in
item responses will be analyzed for
relationship to CBO characteristics (e.g.,
clinical CBOs vs non-clinical CBOs).
Frequency and differences in item
responses will be analyzed across
survey years. We will perform
multivariable analysis as needed (to
assess interactions between time and
type of CBO). The total annualized
burden hours is 165 hours. There are no
other costs to respondents other than
their time.
interventions into their existing
infrastructure. It is unclear whether the
provision of and capacity to provide
nPEP, PrEP, and TasP has increased
among CBOs since the original survey
was conducted. Furthermore, it is
unclear whether non-clinical CBOs have
achieved parity in linking clients to
biomedical HIV prevention
interventions with their clinical
counterparts. This new survey will
assess current capacity and provision of
nPEP, PrEP, and TasP among CBOs
providing HIV services to populations
with increased risk for HIV acquisition.
In addition, the results of this survey
will be compared to the results of the
2015 survey to assess differences in
awareness, capacity, and provision of
biomedical HIV prevention
interventions. Respondents will include
organizations engaged in HIV
prevention and outreach. Up to 330
respondents (N=330; 175 funded CBOs
and 155 CBOs that did not receive
funding) will be recruited to complete
the survey. This project will employ a
cross-sectional survey design. All CBOs
within each of the two strata (1. Clinical
and non-clinical CBOs directly funded
by CDC, and 2. Clinical and non-clinical
CBOs that did not receive CDC funding)
will receive phone calls to elicit interest
in participating in the survey and to
receive the contact information of an
organization’s representative to
complete the survey on behalf of the
organization. Potential respondents will
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Total burden
(in hours)
Form name
Community Based Organization .......
Community Based Organization HIV
Prevention Needs Assessment
Survey.
330
1
30/60
165
Total ...........................................
...........................................................
........................
........................
........................
165
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2020–04721 Filed 3–6–20; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2020–D–0043]
BILLING CODE 4163–18–P
Contact Dermatitis From Topical Drug
Products for Cutaneous Application:
Human Safety Assessment; Draft
Guidance for Industry; Availability
jbell on DSKJLSW7X2PROD with NOTICES
Average
burden per
response
(in hours)
Number of
responses per
respondent
Type of respondents
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
SUMMARY:
VerDate Sep<11>2014
17:47 Mar 06, 2020
Jkt 250001
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
announcing the availability of a draft
guidance for industry entitled ‘‘Contact
Dermatitis From Topical Drug Products
for Cutaneous Application: Human
Safety Assessment.’’ This draft guidance
provides recommendations for the
characterization, during product
development, of local safety of topical
drug products regarding the risk for
contact dermatitis. These
recommendations are specifically
directed to development of topical new
drug products intended for cutaneous
application.
Submit either electronic or
written comments on the draft guidance
DATES:
E:\FR\FM\09MRN1.SGM
09MRN1
Agencies
[Federal Register Volume 85, Number 46 (Monday, March 9, 2020)]
[Notices]
[Pages 13656-13657]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-04721]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-20-20HR; Docket No. CDC-2020-0019]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
Federal agencies the opportunity to comment on a proposed and/or
continuing information collection, as required by the Paperwork
Reduction Act of 1995. This notice invites comment on a proposed
information collection project titled Community-Based Organizations'
Changes in Preparedness and Resources for Support of Biomedical HIV
Prevention. The information collection project will be used to assess
community-based organizations' (CBOs) awareness of, intentions to
provide, and provision of Treatment as Prevention (TasP), non-
occupational post-exposure prophylaxis (nPEP), or pre-exposure
prophylaxis (PrEP) among clinical and non-clinical CBOs that have
received funding from CDC's Division of HIV/AIDS Prevention (DHAP) and
those that applied but did not receive funding.
DATES: CDC must receive written comments on or before May 8, 2020.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2020-
0019 by any of the following methods:
Federal eRulemaking Portal: Regulations.gov. Follow the
instructions for submitting comments.
Mail: Jeffrey M. Zirger, Information Collection Review
Office Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS-D74, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without change, all relevant comments
to Regulations.gov.
Please note: Submit all comments through the Federal eRulemaking
portal (regulations.gov) or by U.S. mail to the address listed above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Jeffrey M. Zirger, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road NE, MS-D74, Atlanta, Georgia 30329; phone: 404-639-7570; Email:
[email protected].
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
Federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected; and
4. Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submissions of responses.
5. Assess information collection costs.
Proposed Project
Community-Based Organizations' Changes in Preparedness and
Resources for Support of Biomedical HIV Prevention--New--Division of
HIV/AIDS Prevention (DHAP), National Center for HIV/AIDS, Viral
Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
Antiretroviral (ARV) medications can be effectively used to reduce
the number of new HIV infections. In persons without HIV infection,
ARVs can be given as either: (1) For 28 days following a potential HIV
exposure through sexual or injection behaviors as nPEP or (2) begun
before potential sexual HIV exposures and taken daily for months to
years as PrEP. In persons with HIV infection, beginning treating with
ARVs early in their infection (e.g., with high CD4 cell counts) can
greatly lower their risk of transmitting infection
[[Page 13657]]
to uninfected sexual partners; this is also called treatment as
prevention or TasP. PrEP is 99% effective at reducing the risk of HIV
through sexual contact when taken daily. PrEP is also 74%-84% effective
at reducing the risk of HIV infection through injection drug use when
taken daily. Persons living with HIV who are taking ARVs as prescribed
as well as achieving viral suppression effectively have no risk for
transmitting the virus to an HIV-negative partner through sexual
contact. CDC is working with various jurisdictions with high HIV
prevalence to increase capacity of ARV provision, build collaborative
efforts between health departments and community-based organizations,
and engage multi-sector provider systems to reach individuals with high
risk of HIV infection as part of the End the HIV Epidemic Initiative.
CBOs will play a crucial role in the End the HIV Epidemic Initiative.
In a previous survey conducted by CDC's Division of HIV/AIDS
Prevention, CBOs reported high awareness of nPEP, PrEP, and TasP, but
their ability to meet client need was low. Although clinical CBOs were
more prepared to support the expansion of biomedical HIV prevention
interventions, the likelihood that all CBOs would incorporate these
interventions if they had additional resources was somewhat high.
Research is needed to better understand the capacity of CBOs to
incorporate biomedical HIV prevention interventions into their existing
infrastructure. It is unclear whether the provision of and capacity to
provide nPEP, PrEP, and TasP has increased among CBOs since the
original survey was conducted. Furthermore, it is unclear whether non-
clinical CBOs have achieved parity in linking clients to biomedical HIV
prevention interventions with their clinical counterparts. This new
survey will assess current capacity and provision of nPEP, PrEP, and
TasP among CBOs providing HIV services to populations with increased
risk for HIV acquisition. In addition, the results of this survey will
be compared to the results of the 2015 survey to assess differences in
awareness, capacity, and provision of biomedical HIV prevention
interventions. Respondents will include organizations engaged in HIV
prevention and outreach. Up to 330 respondents (N=330; 175 funded CBOs
and 155 CBOs that did not receive funding) will be recruited to
complete the survey. This project will employ a cross-sectional survey
design. All CBOs within each of the two strata (1. Clinical and non-
clinical CBOs directly funded by CDC, and 2. Clinical and non-clinical
CBOs that did not receive CDC funding) will receive phone calls to
elicit interest in participating in the survey and to receive the
contact information of an organization's representative to complete the
survey on behalf of the organization. Potential respondents will be
contacted from a list of CBOs that completed the 2015 survey. In
addition, CBOs that received DHAP funding through PS15-1502 and PS17-
1704 will also be contacted to determine their interest in
participating in the data collection effort and to nominate a staff
member to complete the survey. Each organization's representative will
receive an email with a link to the survey website (created with Survey
Monkey). The email will instruct the representative on how to complete
the survey. Three email reminders will be sent to organizations for
those that do not complete the survey. Where possible, data from the
2015 survey will be combined with data from the 2020 survey. Analyses
will include completeness (non-response rates per item) as well as
frequency of item responses for awareness, intentions, and provision of
PrEP, nPEP, and TasP will be assessed for all respondents combined.
Frequency and differences in item responses will be analyzed for
relationship to CBO characteristics (e.g., clinical CBOs vs non-
clinical CBOs). Frequency and differences in item responses will be
analyzed across survey years. We will perform multivariable analysis as
needed (to assess interactions between time and type of CBO). The total
annualized burden hours is 165 hours. There are no other costs to
respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per Total burden
Type of respondents Form name respondents responses per response (in (in hours)
respondent hours)
----------------------------------------------------------------------------------------------------------------
Community Based Organization.. Community Based 330 1 30/60 165
Organization
HIV Prevention
Needs
Assessment
Survey.
---------------------------------------------------------------
Total..................... ................ .............. .............. .............. 165
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2020-04721 Filed 3-6-20; 8:45 am]
BILLING CODE 4163-18-P